Nonionic Surfactant Mediator for Vascular Disorder Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pharmaceutical preparations for intravenous administration, such as fosaprepitant, often cause vascular disorders like angialgia or vasculitis, which can deter patients from treatment due to their frequency and associated side effects, and existing solutions like dexamethasone have significant side effects, making it challenging to manage these issues effectively.
Innovation Solution
A composition containing 1 part or more of a nonionic surfactant, such as polyoxyethylene castor oil, polysorbate, or polyoxyethylene hydrogenated castor oil, relative to 1 part of a water-soluble drug causing vascular disorders, is used to alleviate vascular disorders by reducing cytotoxicity and preventing tissue contact with high-concentration drug solutions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If dexamethasone is used to suppress inflammation caused by water-soluble drugs, then vascular disorder symptoms are alleviated, but various side effects occur and management becomes difficult
Solution Approach 1:
A nonionic surfactant is introduced as an intermediary substance between the water-soluble drug and the blood vessels. The surfactant forms a protective interface that prevents direct contact between the cytotoxic drug and vascular tissues, thereby suppressing vasculitis and angialgia without requiring anti-inflammatory steroids like dexamethasone.
Solution Approach 2:
The invention converts the harmful cytotoxicity of the water-soluble drug into a beneficial effect by using the nonionic surfactant to control drug distribution. The surfactant ensures the drug reaches its therapeutic target while preventing contact with sensitive vascular tissues, thus transforming a potentially harmful interaction into a controlled therapeutic process.
2Reliability
If water-soluble drugs are administered intravenously, then therapeutic effect is achieved, but vascular disorder such as vasculitis or angialgia occurs with onset frequency of 20% or more
Solution Approach 1:
The nonionic surfactant serves as a mediator that facilitates safe intravenous administration of water-soluble drugs. It creates a protective interface between the drug solution and blood vessels, enabling reliable drug delivery while preventing vascular disorders that occur in over 20% of conventional administrations.
Solution Approach 2:
The invention changes the physical-chemical parameters of the drug solution by adding nonionic surfactant. This modification alters the surface properties and cytotoxicity characteristics of the solution, allowing it to be administered intravenously without causing vasculitis or angialgia, thus maintaining therapeutic reliability while eliminating harmful effects.
3Power
If high-concentration drug solution is administered, then therapeutic efficacy is improved, but cytotoxicity and vascular disorder risk increase
Solution Approach 1:
The nonionic surfactant acts as a protective intermediary that enables administration of high-concentration drug solutions. It forms a protective barrier around the drug molecules, allowing them to maintain high therapeutic concentration while preventing direct cytotoxic interaction with vascular and tissue cells.
Solution Approach 2:
The addition of nonionic surfactant changes the cytotoxicity parameters of the drug solution without affecting its therapeutic potency. This parameter modification allows the solution to be administered at high concentrations needed for effective therapy while the surfactant prevents harmful cytotoxic effects on surrounding tissues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of nonionic surfactants significantly reduces vascular disorders, such as vasculitis and angialgia, associated with water-soluble drugs, thereby improving patient outcomes and reducing side effects, as demonstrated by reduced pathological scores in blood vessel stimulation tests.
Implementation Method 1
a composition containing a water-soluble drug causing vascular disorder, wherein the composition comprises 1 part by mass or more of a nonionic surfactant with respect to 1 part by mass of the water-soluble drug causing vascular disorder
Data Source
AI summary
Alleviation of vascular disorder such as vasculitis or angialgia is required in the use of a water-soluble drug causing vascular disorder. According to the present invention, a composition containing a water-soluble drug causing vascular disorder; a solution for use in preparation of an administration solution containing a water-soluble drug causing vascular disorder; and a kit including a water-soluble drug preparation causing vascular disorder and the aforementioned solution, each of which contains a nonionic surfactant in an amount necessary for alleviation of vascular disorder, are provided.